Table 2.
Investigations | Results | Interpretation | Normal range |
Heterophile Ab | Positive | Positive | Negative |
EBV VCA IgM EIA | >160.0 | Positive | ≤35.9 U/mL (negative) |
EBV VCA IgG EIA | 99.9 | Positive | ≤17.9 U/mL (negative) |
EBV EA Ab EIA | >150.0 | Positive | ≤8.9 U/mL (negative) |
EBNA IgG EIA | <3.0 | Negative | ≤17.9 U/mL (negative) |
CMV IgM Ab | <8.0 | Negative | ≤29.9 AU/mL (negative) |
CMV IgG Ab | 0.23 | Negative | ≤0.59 U/mL (negative) |
CMV PCR | Not detected | Negative | Not detected |
Parvovirus B19 IgM Ab | 1.8 | Positive | ≤0.8 index (negative) |
Parvovirus B19 IgG Ab | 0.2 | Negative | ≤0.8 index (negative) |
Parvovirus B19 IgM Ab* | 1.0 | Negative | ≤0.8 index (negative) |
Parvovirus B19 IgG Ab* | 0.4 | Equivocal | ≤0.8 index (negative) |
*Parvovirus serological tests were repeated 1 week after the initial tests due to the possibility of an initial non-specific polyclonal IgM response.
Ab, antibody; CMV, cytomegalovirus; EBV EA, Epstein-Barr virus early antigen; EBNA, Epstein-Barr virus nuclear antigen; EBV VCA, Epstein-Barr virus viral capsid antigen; EIA, enzyme immunoassay.